Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates

Table 1 Selected criteria sets and satisfaction at baseline among 708 DESIR patients

Criteria set origin	Patients ever satisfying criteria set (n) and percent of total (N = 708)	Diagnosis and disease severity criteria
France	n = 197 (27.8%)	BASDAI ≥4 New York criteria for AS OR involvement of SJ OR spine by X-ray, CT or MRI Physician’s Global Assessment ≥4
Germany	n = 175 (24.7%)	BASDAI ≥4 ASAS criteria Positive MRI or Elevated CRP^b (i.e., minimum 1 of 2 criteria)
Canada	n = 169 (23.8%)	BASDAI ≥4 Sacroiilitis or spinal inflammation on X-ray, CT or MRI Elevated CRP or ESR and/or Inflammatory lesions in the sacroiliac joints and/or spine on MRI and/or Expert opinion^a (Minimum 2 of 3 criteria)
United Kingdom	n = 86 (12.1%)	BASDAI ≥4 Modified New York criteria for AS Spinal pain in last week 4/10 VAS
Hong Kong	n = 61 (8.6%)	BASDAI ≥4 Modified New York criteria for AS Morning stiffness ≥45 min Inflammatory back pain ≥40/100 VAS Patient Global Assessment ≥40/100 VAS

CT computerized tomography, MRI magnetic resonance imaging, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, AS ankylosing spondylitis, CRP C-reactive protein, ESR erythrocyte sedimentation rate, SJ sacroiliac joint, VAS visual analogue scale
^aPositive expert opinion defined in the analysis as Physician’s Global Assessment ≥4
^bNA at baseline, values reported for month 6

ISSN: 1478-7547